Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43279| Title: | Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited | Authors: | Fokas, Emmanouil Smith, J. Joshua Garcia-Aguilar, Julio Glynne-Jones, Robert BUYSE, Marc Roedel, Claus |
Issue Date: | 2024 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | Journal of clinical oncology, 42 (8) , p. 872 -875 | Abstract: | Trial-level surrogacy is critical before early response endpoints are used to approve new therapies. | Notes: | Fokas, E (corresponding author), Goethe Univ Frankfurt, Dept Radiotherapy & Oncol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany. emmanouil.fokas@kgu.de |
Keywords: | Humans;Treatment Outcome;Neoadjuvant Therapy;Rectal Neoplasms | Document URI: | http://hdl.handle.net/1942/43279 | ISSN: | 0732-183X | e-ISSN: | 1527-7755 | DOI: | 10.1200/JCO.23.01196 | ISI #: | 001233983000011 | Rights: | 2023 by American Society of Clinical Oncology. Free access | Category: | A2 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| fokas-et-al-2023-early-efficacy-end-points-in-neoadjuvant-rectal-cancer-trials-surrogacy-revisited.pdf | Published version | 354.06 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.